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Abstract
Background:  The active copy of the imprinted gene H19 is turned off by inappropriate
methylation in several pediatric tumors including Wilms' Tumour and embryonal
rhabdomyosarcoma. H19 controls in cis the linked Insulin-like Growth Factor 2 (IGF2) gene, encoding
an important growth factor. Recent work has suggested that methylation of a gene may lead to
deacetylation of its associated histones and that silenced genes can be reactivated by increasing
histone acetylation levels.
Results: Treatment of a rhabdomyosarcoma cell line which has a silent, methylated H19 gene with
histone deacetylase (HDAC) inhibitors under conditions which gave maximal hyperacetylation of
histone 4, both globally and at the H19 gene itself could not reactivate H19 or affect the active
Insulin-like Growth Factor 2 (IGF2) gene, but caused clear up-regulation of the Tissue-type Plasminogen
Activator (TPA) gene, a non-imprinted gene known to respond to changes in histone acetylation. In
contrast, mild treatment of the cells with the methylation inhibitor 5-AzaC-2'-deoxycytidine
(AzaC) on its own was able to reactivate H19. Combining AzaC treatment with HDAC inhibitors
gave a reduced rather than enhanced reactivation. These findings were confirmed in mouse primary
liver and kidney explants which maintain normal imprinting, where we also found that the silent Igf2
gene could not be reactivated by HDAC inhibitors.
Conclusion: These results suggest that DNA methylation rather than histone acetylation is the
primary determinant of silencing of H19 in rhabdomyosarcoma.
Background
Inactive genes in mammals often have particular features
which differentiate them from their active neighbours.
High levels of DNA methylation have been found to be as-
sociated with a large number of inactive endogenous
genes in normal tissues and also with many genes which
are aberrantly silenced in tumour cells [1]. In contrast,
high levels of histone acetylation are associated with tran-
scriptionally active genes [2]. DNA methylation and his-
tone deacetylation have also been mechanistically linked,
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since it has been found that proteins which bind to meth-
ylated cytosine such as MeCP2 can recruit HDACs [3].
Treatment of cancer cell lines with demethylating agents
can cause reactivation of certain silenced tumor suppres-
sor genes and this effect was augmented for some by the
addition of HDAC inhibitors such as Trichostatin A (TSA)
or the chemotherapeutic agent sodium butyrate [4]. This
raises the possibility that a combination of agents which
inhibit DNA methylation and promote histone acetyla-
tion may lead to efficient reactivation of growth-inhibito-
ry genes in certain cancers, including those which
currently have a poor response to chemotherapy such as
rhabdomyosarcoma.
Two genes which are known to be effected by changes in
DNA methylation and which are implicated in rhab-
domyosarcoma, are the imprinted genes H19 and IGF2,
which are tightly linked on human chromosome 11p15
[5]. IGF2 encodes a fetal growth factor and is expressed
only from that copy of chromosome 11 inherited from
the father, while H19 is expressed exclusively from the
maternally inherited allele. The inactive paternal copy of
H19 is heavily methylated and is less accessible to nucle-
ases, while the maternal copy is unmethylated and in a
more open conformation [6]. H19 and IGF2 compete for
shared enhancer elements: methylation of the paternal
H19 allows IGF2 to gain control of the enhancers and be-
come expressed [7]. The importance of methylation has
been demonstrated in mice with decreased levels of meth-
ylation, which show expression of H19 from both alleles
and a loss of Igf2 expression [8]. Besides rhabdomyosarco-
ma, H19 and IGF2 have been implicated in a number of
other human cancers [9]. In many cases, the primary le-
sion appears to be not a deletion or point mutation, but
rather a change in methylation, usually an aberrant meth-
ylation of the maternal H19 allele [10–12]. Since this
renders both alleles methylated, it has the effect of silenc-
ing H19 and results in a concomitant biallelic expression
of IGF2. In Wilms' tumors, a pediatric tumor of the kid-
ney, inactivation of H19 by methylation is almost as com-
mon as loss of heterozygosity (LOH) and thus represents
a significant pathway for inactivation of a growth-inhibit-
ing gene in tumors [12].
In order to assess the possibility for reactivating H19 in
rhabdomyosarcoma, we set out to determine whether
treatment of a recently-derived line of rhabdomyo-sarco-
ma cells with histone deacetylases, on their own, or in
combination with inhibitors of DNA methylation, could
cause a significant reactivation of a silenced H19 allele.
We found that the silenced allele is unresponsive to inhib-
itors of deacetylation, while it could be reactivated readily
using an inhibitor of methylation. A combination of the
two treatments carried out simultaneously resulted in less
reactivation than seen for the methylation inhibitor on its
own, rather than more. These experiments indicate that
methylation and not acetylation is the primary determi-
nant of aberrant H19 silencing in this tumor type.
Results
Treatment with HDAC inhibitors increases acetylation lev-
els globally and at the H19 locus without relieving silencing 
of the gene
In order to investigate the effects of increasing histone
acetylation levels in RD cells on the silenced H19 gene,
cells were grown in culture medium supplemented with a
range of concentrations of TSA from 25 nM to 1 mM for
periods ranging from 3 hrs to 2 weeks and sodium butry-
ate (3 mM) for various times from 3 hrs to 24 hours. Pro-
teins were then extracted and analyzed by Western
blotting using an antibody against acetylated histone 4.
Histone acetylation levels are maximally effected by in-
hibitors at very early time points, with the increase in his-
tone acetylation dropping off rapidly in the first day of
treatment and protein samples taken on subsequent days
of treatment showed no difference between treated and
untreated cells. This effect can be seen in Figure 1, where
RD cells were treated with 500 nM TSA for 6 or 15 hours,
after which proteins were harvested and analysed by West-
ern hybridisation with an antibody to the acetylated form
of histone 4. At 6 hr, acetylation levels have strongly in-
creased (Fig 1A, lanes 1 and 2), but this effect has dimin-
ished significantly at 15 hr (Fig 1A, lanes 3 and 4): by 48
hrs, no difference in acetylation levels between treated
and untreated samples can be detected (data not shown).
Increases in histone acetylation levels were equivalent at 3
hr and 6 hr (data not shown). These data agree with recent
studies showing cells can homeostatically adjust to main-
tain a steady-state level of histone acetylation [13]. Treat-
ment with sodium butyrate (3 mM), another inhibitor of
histone deacetylases (HDACs) showed similar effects to
500 nM TSA and results are shown for TSA alone.
In order to ensure that the alterations in histone acetyla-
tion were meaningful in terms of gene transcription, we
examined the transcription levels of TPA, which has previ-
ously been shown to be up-regulated by hyperacetylation
[14]. Levels of transcription of the TPA gene increase in
proportion to the level of acetylation seen at histone 4
(Fig 1C): at 6 hr post-treatment, TPA mRNA levels are sig-
nificantly increased, while at 15 hr only a slight increase
in transcript levels can be seen (Fig 1C, lanes 2 and 4).
Taken together with the observations above, this indicates
that the cell can compensate for the presence of HDAC in-
hibitors on prolonged treatment, possibly by up-regulat-
ing the enzymes. This is a significant finding, since many
previous studies using these drugs have looked at gene
transcription after treatments of 15 hr or more. However,
robust effects on acetylation levels and gene transcription
are achieved at shorter timepoints.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/2
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We examined expression of H19 in the cells treated with
500 nM TSA for 6 hr (which show hyperacetylation of his-
tones) by stripping the membrane used to probe for TPA
and rehybridising with an H19 probe. No reactivation of
the gene could be seen (Fig 1D, lanes 1 and 2). Treatment
with concentrations of TSA from 25 nm to 1 mM for peri-
ods up to 12 days or with sodium butyrate at 3 mM for up
to 15 hrs also failed to cause any detectable increase in
H19 transcription. However, treatment for as little as 15 hr
with 500 nM AzaC, which causes decreases in DNA meth-
ylation, resulted in detectable reactivation of the gene (Fig
1D, lane 5), indicating that even low levels of transcrip-
tion can be detected in this way. We also examined mRNA
levels for the neighbouring IGF2 gene. IGF2 is normally
active in RD cells and no increase or decrease in transcript
levels was seen at 6 hr post-treatment, when acetylation
levels are highest (Fig 1E, lanes 1 and 2). Expression of
IGF2 increases during the log phase of cell growth, so that
levels in untreated cells are higher at 15 hr (Fig 1C, lane 3)
than they were at 6 hr: cells grown for 15 hours in the pres-
ence of 500 nM TSA or 500 nM AzaC show a slight de-
crease in IGF2expression which is most likely to be due to
the differentiating effect of these two drugs.
It is possible that histones at the H19 and IGF2 locus are
particularly refractory to inhibitors of histone deacetylas-
es. In order to test this possibility, we carried out chroma-
tin immunoprecipitation experiments to assay whether
changes in acetylation levels occur at the H19 locus on
treatment with TSA. Chromatin was cross-linked to DNA
using formaldehyde, sonicated to reduce the fragment
size, then immunoprecipitated with the anti-acetylated
H4 antibody. PCR using primers located in the tran-
scribed region (Region 1) or in the upstream insulator re-
gion (Region 2) of the H19 gene were used to determine
the fraction of total templates which are associated with
acetylated histone 4. Input DNA (Fig 2, lanes 1 and 3, In)
which has not been treated was used as a control between
samples, while a sample of DNA which has been mock-
immunoprecipitated without antibody was used as a neg-
ative control (Fig 2, lanes 5 and 6, No Ab). We found that
after treatment with TSA there was a reproducible increase
in the amount of acetylated H4 associated with both the
transcribed and the upstream regions (Fig 2A and 2B).
Each experiment was carried out independently at least
three times. These results indicate that H4 acetylation lev-
els are being increased at the H19 locus in these experi-
ments, but with no detectable effect on H19 transcription.
Reactivation of H19 by demethylation is inhibited by TSA
It has been suggested that some epigenetically silenced
genes can only be reactivated by treatment with a combi-
nation of histone deacetylase inhibitors and methylation.
In order to test whether such a combination treatment
might enhance the reactivation of H19 in rhabdomyosar-
Figure 1
Effects of histone deacetylase inhibitor on rhabdomy-
osarcoma cells. Cells were treated for 6 hr (lanes 1, 2) or
15 hr (lane 3–5) with 500 nM of either Trichostatin A (TSA)
or 5'-aza-2'deoxycytidine (AzaC) as indicated at top. (A)
Western analysis of protein derived from the cells using the
anti-acetylated histone 4 (AcH4) antibody shows that treat-
ment with TSA markedly increases the amount of acetylated
histone in the cells at 6 hr (lanes 1 and 2). While treatment
for 15 hr also increases acetylation levels, the effect is less
marked, presumably due to a compensatory mechanism in
the cell (lanes 3 and 4). (B) Coomasie stained total protein
loading control for the Western. (C) Northern hybridization
of RNA derived from the same cells to a probe for Tissue-
type Plasminogen Activator (TPA). Transcription levels can be
seen to increase in parallel with the marked increase in his-
tone acetylation (lanes 1 and 2), indicating that acetylation
plays an important role in determining levels of TPA tran-
script in the cell. The less marked increase in acetylation seen
at 15 hr has only a slight effect on transcript levels (lanes 3
and 4). (D) The membrane used in (C) was stripped and
rehybridized with a probe for H19, which is normally silent in
these cells. No signal was detected in the normal or TSA-
treated samples (lanes 1–4), but some reactivation could be
seen after even a brief treatment with a low level of AzaC
(lane 5). (E) Rehybridization with an IGF2 probe shows no
difference between the TSA treated and untreated samples
at 6 hr (lanes 1 and 2) or 15 hr (lanes 3 and 4). IGF2 tran-
scripts accumulate in the cells during the log phase of growth
in culture and at 15 hr, basal levels of IGF2 have increased
from those seen at 6 hr (compare lanes 3 and 1). The two
major IGF2 transcripts of 6 kb and 4.9 kb are visible. (F) 28S
rRNA loading control for the Northern.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/2
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coma seen using methylation inhibitor alone, we grew RD
cells for long or short periods in various combinations of
AzaC and TSA. Both long and short-term cultures gave
similar results and a typical experiment can be seen in Fig-
ure 3 (treatment for 1 week). Here, the silenced H19 allele
shows a dose-dependent reactivation in response to AzaC
treatment, with higher levels of the drug (0.5 mM to 1
mM) resulting in greater activation (Fig 3A, lanes 1–5).
Addition of 500 nM TSA to the culture medium contain-
ing various amounts of AzaC resulted in a significant de-
crease in the level of H19 transcript produced (Fig 3A,
lanes 6–10). A decrease in IGF2 transcript levels on addi-
tion of TSA was also seen in these cells when compared to
treatment with AzaC alone (Fig 3B). These results indicate
that a combination of drug treatments do not result in an
increase in H19 expression, but rather inhibit reactivation
of the gene by demethylation.
Igf2 and H19 transcript levels in primary cells are not ef-
fected by inhibitors of histone acetylation
H19 and IGF2 expression are highest in embryonal tis-
sues, and silencing of the active allele has been seen in
normal fetal tissues prior to tumor formation. In order to
extend our findings from the embryonal rhabdomyosar-
coma-derived cell line RD to primary cells and to provide
for sensitive detection of reactivation of a silent Igf2 allele,
we developed an assay based on explanting fetal tissues
from normal mice or mice with a homozygous deletion of
the Igf2 gene. Each liver or kidney from an embryonic day
16.5 fetal mouse was dissected out and dissociated into a
single-cell suspension prior to splitting between four wells
Figure 2
Chromatin immunoprecipitation assay of histone acetylation at the H19 locus in treated rhabdomyosarcoma
cells. Cells were either treated (TSA) or not treated (Con; control) with histone deacetylase inhibitor (500 nM TSA for 6 hrs).
DNA and proteins were cross-linked and precipitated with an antibody to acetylated histone 4, prior to reversing cross-links,
amplifying DNA with specific primers and separating the products on a gel. (A) Results obtained using primers specific for the
transcribed region of the H19 gene (Region 1), which give an expected band size of 355 bp. Equal amounts of input DNA (In)
were used in each immunoprecipitation (lanes 1 and 3) and a no antibody control was run for each sample (lanes 5 and 6).
Treatment with TSA gives an increase in signal for the 355 bp target, indicating an increase in acetylated histones associated
with the transcribed region (lanes 2 and 4). (B) Primers for a region in the insulator (Region 2) upstream of H19 and down-
stream of IGF2 give a specific band of 161 bp and this also shows a marked increase after TSA treatment of the cells. Controls
are as for (A) above. M; 1 kb DNA size marker (Life Tech.). Minor bands present in some lanes represent non-specific artifacts:
primers are visible at the bottom of the gel. Negative images of ethidium-stained gels are shown.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/2
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of a six-well tissue-culture plate. Cells from both kidney
and liver formed large patches of cuboidal epithelia inter-
spersed with fibroblast cells. Two of the four wells were
treated with a histone deacetylase inhibitor for 6 hr and
two were left untreated. Protein extract was prepared from
one treated and one untreated sample and the remaining
treated and untreated sample were used to prepare RNA.
Treatment of primary liver or kidney cells which had never
been passaged with 500 nM TSA or 3 mM Sodium bu-
tyrate for 6 hr resulted in a marked increase in H4 acetyla-
tion, as seen previously in RD cells: results are shown for
liver cell cultures (Fig 4A). This also resulted in an up-reg-
ulation of the mouse tissue-type plasminogen activator
gene (Tpa) (Fig 4C), indicating that histone acetylation
levels were again being altered to a degree significant
enough to effect gene transcription. We found that Igf2
imprinting was maintained in these primary cells, as
shown by the lack of expression of the gene in the cultures
derived from a mouse with a paternally-inherited Igf2
knockout (Fig 4D, lanes 1–2), whereas Igf2 transcripts
were detected in liver explants from wild-type littermates
(Fig 4D, lanes 3–4). However, no significant reactivation
of the silent maternal Igf2 allele from any of the three em-
bryonic promoters was seen in the samples, even on long
exposure of autoradiographs (Fig 4D and data not
shown). There was no significant effect seen on the active
Igf2 or H19 alleles in this system. Results for sodium
butryrate were identical to TSA and no effect of inhibitors
on transcription was seen on longer-term culturing of cells
(2–15 days) or in primary kidney cells (data not shown).
Figure 3
Simultaneous treatment of cells to increase histone acetylation and decrease DNA methylation. Rhabdomyosa-
rcoma cells were treated with the indicated amounts of AzaC in the absence (lanes 1–5) or presence (+TSA; lanes 6–10) of
500 nM TSA. RNA was extracted and separated on an agarose gel before transferring to a nylon membrane and hybridizing
with the indicated probes. (A)H19 transcription is reactivated by AzaC in a dose-dependent fashion with higher doses result-
ing in greater reactivation (lanes 1–5). Combining the AzaC treatment with 500 nM TSA however results in lower levels of
reactivation of the gene (compare lanes 6–10 with lanes 1–5). (B) The same membrane stripped and rehybridized with a probe
for IGF2. Levels of IGF2 show a slight decrease as H19 transcription increases in the cells treated with AzaC alone (lanes 1–5).
H19 and IGF2 compete for common enhancer elements, which would explain this effect. The effect is diminished in cells
treated with both TSA and AzaC (lanes 6–10), which also show less H19 expression. (C) 28S rRNA loading control for the
Northern.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/2
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Discussion
There is growing evidence for the existence of a pathway
to gene inactivation in cancer which does not involve the
loss or alteration of the primary sequence of DNA, but
rather a change in the activation status of the gene through
epigenetic means [1]. Alterations in DNA methylation
have been the type of epigenetic change most closely stud-
ied and it has been found that hypermethylation is asso-
ciated with the silencing of key genes in many cancers
[15,16]. Inactivation of the H19 gene by methylation is
implicated in a number of childhood cancers, including
Wilms' tumour and embryonal rhabdomyosarcoma [12].
Wilms' tumors (WT) often occur in association with Beck-
with-Weidemann Syndrome (BWS) and it is the subset of
BWS patients with methylation of the maternal allele of
H19 which usually develop WT [17,18]. In some cases of
BWS and of Wilms' tumors the methylation and inactiva-
tion of the H19 gene is seen in preneoplastic kidney tissue,
indicating that it is an early event in tumorigenesis [10–
12]. The H19 gene is part of a cluster of imprinted genes
on human chromosome 11p15 which includes the IGF2
gene and several others [12]. In normal tissues, methyla-
tion on the paternal allele of H19 inactivates the promoter
of the gene. In addition, there is a region upstream which
acts as an insulator, preventing Igf2 from interacting with
the enhancers downstream of H19 on the maternal allele.
On the paternal allele, the insulator, like the H19 promot-
er, is also methylated and inactivated, allowing IGF2 to in-
teract with the enhancers. The maternal LOH commonly
seen in tumors such as WT and RD eliminates the active
maternal H19 gene and usually duplicates the active pater-
nal IGF2 gene. Methylation of the normally unmethylated
maternal H19 allele in these tumors has a similar effect, as
both copies of H19 are now silent and IGF active bialleli-
cally. Deletion of the H19 locus or of the insulator up-
stream [7] by homologous recombination in mice causes
the silent maternal allele of Igf2 to become active. In con-
trast, removal of methylation from the maternal H19 gene
by inactivation of the major methyltransferase activity in
the cell causes activation of the silent paternal H19 allele
and a concomitant decrease in Igf2 expression [8]. Treat-
ment of RD cells by AzaC has also been shown previously
to have this effect [5].
Recent work has indicated that DNA methylation and his-
tone deacetylation may act along the same pathway of in-
activation. Three proteins which bind to methylated DNA,
MeCP2, MBD1 and MBD2 have been shown repress tran-
scription through a mechanism which involves histone
deacetylases [3]. Additionally, both the major DNA meth-
yltransferase enzyme DNMT1 [19] and the CTCF protein
[20] which binds the upstream insulator region between
H19 and IGF2 may cause histone deacetylation either di-
rectly or by interacting with HDACs. The inactive alleles of
H19 and Igf2 have also recently been shown to have lower
Figure 4
Effects of histone deacetylase inhibitor on Igf2 knock-
out cells. Primary embryonic liver cells were derived from
mice which carried a paternally-inherited deletion of Igf2 (Pat
KO; lanes 1 and 2) or their wild-type littermates (WT; lanes
3 and 4). First passage cells were either treated with 500 nM
TSA for 6 hr or left untreated as indicated. (A) Western
analysis of protein derived from the cells using the anti-
acetylated histone 4 (AcH4) antibody shows that treatment
with TSA markedly increases the amount of acetylated his-
tone in the primary cells (lanes 2 and 4). (B) Coomasie
stained total protein loading control for the Western. (C)
Northern hybridization of RNA derived from the same cells
to a mouse probe for Tissue-type plasminogen activator (Tpa).
Transcription levels can be seen to increase on TSA treat-
ment (lanes 2 and 4) as in RD cells. (D) The membrane used
in (C) was stripped and rehybridized with a probe for Igf2.
Mice which carry a deletion of the gene on the paternally
inherited allele (Pat KO) are missing the allele which is nor-
mally active but retain the silenced maternal allele and show
no expression of the gene (lane 1). Reactivation of the silent
maternal allele was not seen in the cells treated with TSA
(lane 2). The two major transcripts ran as a single band here.
(E) Rehybridization with an H19 probe shows no significant
difference between the TSA treated and untreated samples,
allowing for differences in loading. (F) 28S rRNA loading
control for the Northern.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/2
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levels of histone acetylation than their active counterparts
[21], as would be expected if methylation and deacetyla-
tion were coupled. If methylation must be followed by
histone deacetylation to inactivate a gene, then it is possi-
ble that reacetylation of histones associated with a si-
lenced gene may be sufficient to relieve repression and
allow transcription. Alternatively, it may be necessary to
use a combined treatment which both demethylates the
gene and acetylates its associated histones to reactivate a
silenced gene.
We found in the work described here that the HDAC in-
hibitors TSA and sodium butyrate did cause clear increas-
es in H4 acetylation both globally and at the H19 locus in
RD cells treated for 6 hrs with these drugs. These increases,
while insufficient to reactivate the silent H19 gene, caused
up-regulation of the already active TPA gene, which has
previously been shown to be responsive to changes in his-
tone acetylation levels [14]. This is similar to the findings
of Cameron et al, who showed that TSA alone could up-
regulate the basally transcribed CDKN2B and CDKN1A
(p21) genes, but not reactivate the silent MLH1 and TIMP3
genes in the colorectal carcinoma cell line RKO [4]. Our
results also agree with previous work in mice [22], where
it was found that TSA did not reactivate the silenced H19
allele in the vast majority of cells in the mouse embryo.
TSA failed to reactivate H19 in RD cells at any concentra-
tion from one low enough to show no effect on histone
acetylation (25 nM) to a level high enough to have signif-
icant cytotoxic side-effects (1 mM) and for any length of
time tested from 6 hr to 12 days. In contrast to these re-
sults, treatment of RD cells with as little as 500 nM AzaC
for a period as short as 15 hrs was sufficient to reactivate
H19 in some RD cells, indicating that methylation is a far
more important determinant of H19 inactivation in RD
cells. These results agree with earlier findings from treat-
ment of RD cells [5] or cells from uniparental embryos
[23] with AzaC and also with studies on mice deficient in
Dnmt1 activity [8,24]. H19 seems particularly sensitive to
changes in methylation levels compared to other imprint-
ed genes in the same cluster as shown by our previous
work [12] and that of other laboratories [24,25].
Cameron et al had also found that treatment of cells with
a combination of HDAC and methylation inhibitors
could reactivate silent genes which were unresponsive to
the HDAC inhibitors alone [4]. While Pedone and co-
workers found that H19 could be reactivated in this way
in cultured mouse fibroblasts when RT-PCR assays were
used for detection [26], our own results from RD cells pre-
sented here and those of El Kharroubi et al from cultured
mouse fibroblasts [23] show that treatment of cells with
both types of inhibitor together in fact decreases the levels
of H19 mRNA detected relative to those seen with AzaC
treatment alone. We found this to be the case at all time-
points and concentrations of inhibitors tested. The evi-
dence therefore suggests that under most circumstances
the silent paternal H19 allele cannot be reactivated by
treatment with HDAC inhibitors on their own or in com-
bination with demethylating agents.
We also found that the silent Igf2 allele could not be sig-
nificantly reactivated on treatment with HDAC inhibitors
in mouse primary cells. Again, this was true of all drug
concentrations and times used, while we could show clear
effects on histone acetylation and on the control gene, Tpa
in this system. The use of cells which were derived from
embryos carrying an Igf2 deletion allowed for sensitive as-
saying for reactivation against a background of zero ex-
pression, similar to the situation for H19 in RD cells. The
results agree with those from RD cells, where no increase
in transcription from the active IGF2 allele is seen on treat-
ment with acetylase inhibitors and are in agreement with
some earlier reports, which have either found no effect
[21,27] or some inhibitory effect [28] of HDAC inhibitors
on Igf2expression. In order to be certain that a significant
reactivation of the silenced Igf2 or H19 is occurring, we
chose to examine expression using Northern blots against
a zero expressing background rather than RT-PCR assays,
which are prone to artifact nonlinearity. It can be noted
that levels of reactivation detected by RT-PCR for p57Kip2
or Peg3 in some experiments using acetylase inhibitors are
only a small fraction of the wild-type levels [23]. We have
previously successfully used Northern blots to detect two-
fold differences in expression of H19 and Igf2 in Dnmt1
mutant mice [29] and in AzaC-treated RD cells [5] and
here we could detect very low levels of H19 expression
which are a result of 15 hr treatment with AzaC (Fig 1B).
We also confined our studies to a very recently-derived cell
line with no H19 expression or to primary mouse cells
which have never been passaged and have a Igf2 null back-
ground, to increase sensitivity. Using these methods, we
found no evidence that hyperacetylation caused signifi-
cant reactivation of Igf2 or H19 in either RD cells or pri-
mary mouse cells.
Conclusions
We find that silencing by DNA methylation in rhabdomy-
osarcoma can be uncoupled from histone acetylation for
the H19 gene. Likewise, methylation and acetylation can
be altered independently in mouse cells carrying a si-
lenced mouse Igf2 gene. These experiments confirm that
methylation is the primary determinant of silencing of the
H19-Igf2 pair in tumour cells and in normal tissues and
that histone hyperacetylation does not reproduce the ef-
fects of demethylation.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/2
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Materials and Methods
Human cell line culture
Cells derived from an embryonal rhabdomyosarcoma cell
line termed RD [5] were grown in DMEM medium con-
taining L-glutamine (Life technologies) supplemented
with 10% fetal bovine serum (Hyclone) and 100 U/ml
penicillin and 100 µg/ml streptomycin (Sigma). Stock so-
lutions of 5-Aza-2'-deoxycytidine (50 mM in DMEM, sin-
gle-use; Sigma), TSA (5 mM in ethanol; Wako chemicals)
or sodium butyrate (50 mM in deionised water; Sigma)
were stored at -85°C and diluted in tissue culture medium
to give the required final concentrations (see text and fig-
ure legends) before being added to cells in the exponential
phase of growth. For experiments in which TSA and AzaC
treatment was carried out simultaneously, TSA was added
directly to medium which contained AzaC.
Mouse breeding and primary tissue explants
For primary tissue explants, male mice heterozygous for
an inactivating mutation at the Igf2 gene (kind gift of A.
Efstratiadis)were crossed to WT C57B6/J females. Preg-
nant females were sacrificed at e16.5 and liver or kidney
collected into prewarmed DMEM medium containing
10% fetal bovine serum and antibiotics as above. Each tis-
sue was triturated through a 23 gauge needle and the cell
suspension used to seed four wells of a six-well plate
which had been pre-treated with fibronectin (Sigma) at
0.5 µg/cm2. After 2 days, the medium was changed to re-
move unattached cells and dead cells – at this stage the re-
maining cells had formed extensive cuboidal epithelia
interspersed with pockets of fibroblast cells. For these first
passage cells, two wells of the four were then treated with
histone deacetylase inhibitors (see text and figure leg-
ends) prior to harvesting protein or DNA.
Protein harvesting and Western analysis
Tissue culture cells were harvested by washing twice in ice-
cold, sterile PBS, then scraped directly in 1:1 dilution of
protein loading buffer (125 mM Tris-OH, 20% glycerol,
6% SDS and 1.4 M 2-mercaptoethanol) in PBS, boiled for
5 mins and chilled on ice/water prior to separation on a
15% SDS/PAGE gel. Western blotting was carried out es-
sentially as described [30]. The primary antibody was anti-
tetraacetylated histone H4 antibody (Upstate Biotech),
used at a dilution of 1:2000 at room temperature for 2 hrs
and the secondary antibody was goat anti-rabbit alkaline
phosphatase (Sigma) used for one hour at room tempera-
ture.
RNA isolation and Northern analysis
RNA was harvested according to standard methods [31].
Cells were initially washed twice with ice-cold, sterile PBS
then lysed and scraped directly in solution D (4 M gua-
nidinium thiocyanate, 25 mM sodium citrate, 0.5% sarc-
osyl, 7 µl/ml 2-mercaptoethanol) before
phenol:chloroform extracting and precipitating twice with
isopropanol. Purified RNA was resuspended in sterile
deionised water. 15 µg of each sample was fractionated by
electrophoresis on formaldehyde containing gels and
transferred to nylon membranes exactly as previously de-
scribed [29].
Probes for RNA blot hybridization analysis
Human Tissue-type plasminogen activator (TPA) exon 13
(Genbank accession no. L00152) was amplified using
primers F1 TGC GGC CTG AGA CAG TAC AG and R1 TCT
CCT GGA AGC AGT GGG CG and cloned into the plas-
mid vector pCR2.1 (Invitrogen). A probe for mouse Tpa
(Genbank accession no. J03520) was generated and
cloned in a similar fashion using the primers F1 GGA TGA
AGG TCT GGC TTT GG and R1 TGG TGC TGT GAT TCG
GCC AG. Human IGF2 and H19 probes have been de-
scribed previously [12]. A rat Igf2 probe used to detect
mouse Igf2 and the mouseH19 probe were as detailed in
[29]. Hybridizations were carried out as in [29].
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation was carried out with the
anti-tetraacetylated histone 4 antibody (Upstate biotech-
nology) as per manufacturer's instructions but with the
following modifications. Chromatin was cross-linked to
DNA in RD cells by adding formaldehyde to the medium
to a final concentration of 1% and incubating at 37°C, 30
mins. Sonication to reduce the size of the cross-linked
DNA was for 3 x 10 sec with cooling on ice between cycles.
The chromatin solution was pre-cleared by adding 60 µl
of a 50% protein A sepharose slurry (Upstate) containing
20 micrograms sonicated salmon sperm DNA and 1 mg/
ml BSA in TE (10 mM Tris; 1 mM EDTA, pH 8.0) and rock-
ing overnight at 4°C. 5 µl anti-acetyl Histone H4 was add-
ed to the resulting supernatant which was then incubated
for 2 h at 4°C with rotation before adding 60 µl of 50%
protein A sepharose/ssDNA slurry and incubating over-
night as before. Proteinase K treatment was done over-
night at 55°C. DNA was recovered by phenol/chloroform
extraction and ethanol precipitation at room temperature
using 20 µg tRNA as a carrier before resuspending in 50 µl
(immunoprecipitated) or 200 µl (input) of water. Specific
sequences were detected using 3 µl input or 5 µl immuno-
precipitated DNA using PCR with the primers H19F11
GCTCCCAGAA CCCACAACA and H19R10 GTGTCTTT-
GATGTTGGGCT for the transcribed region (Region 1: ex-
pected size 355 bp) and H19F5
GCCCTGATGGCGCAGAATC and H19R3 ATGAGTGTC-
TATCTCTGAC for the insulator region (Region 2: expect-
ed size 161 bp). PCR conditions were as follows: an initial
deannealing at 94°C, 3 mins, was followed by 35 cycles of
91°C, 10 sec; 55°C, 30 sec; 68°C, 1 min and one final ex-
tension at 72°C, 7 min.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/2
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